Literature DB >> 11527419

R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism.

R Ramer1, K Brune, A Pahl, B Hinz.   

Abstract

Cannabinoids affect prostaglandin (PG) formation in the central nervous system through as yet unidentified mechanisms. Using H4 human neuroglioma cells, the present study investigates the effect of R(+)-methanandamide (metabolically stable analogue of the endocannabinoid anandamide) on the expression of the cyclooxygenase-2 (COX-2) enzyme. Incubation of cells with R(+)-methanandamide was accompanied by concentration-dependent increases in COX-2 mRNA, COX-2 protein, and COX-2-dependent PGE(2) synthesis. Moreover, treatment of cells with R(+)-methanandamide in the presence of interleukin-1beta led to an overadditive induction of COX-2 expression. The stimulatory effect of R(+)-methanandamide on COX-2 expression was mimicked by the structurally unrelated cannabinoid Delta(9)-tetrahydrocannabinol. Stimulation of both COX-2 mRNA expression and subsequent PGE(2) synthesis by R(+)-methanandamide was not affected by the selective CB(1) receptor antagonist AM-251 or the G(i/o) protein inactivator pertussis toxin. Enhancement of COX-2 expression by R(+)-methanandamide was paralleled by time-dependent phosphorylations of p38 mitogen-activated protein kinase (MAPK) and p42/44 MAPK. Consistent with the activation of both kinases, R(+)-methanandamide-induced COX-2 mRNA expression and PGE(2) formation were abrogated in the presence of specific inhibitors of p38 MAPK (SB203580) and p42/44 MAPK activation (PD98059). Together, our results demonstrate that R(+)-methanandamide induces COX-2 expression in human neuroglioma cells via a cannabinoid receptor-independent mechanism involving activation of the MAPK pathway. In conclusion, induction of COX-2 expression may represent a novel mechanism by which cannabinoids mediate PG-dependent effects within the central nervous system. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527419     DOI: 10.1006/bbrc.2001.5518

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons.

Authors:  Theodore J Price; Amol M Patwardhan; Christopher M Flores; Kenneth M Hargreaves
Journal:  Neuropharmacology       Date:  2005-04-01       Impact factor: 5.250

3.  The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein.

Authors:  J L Fiori; M Sanghvi; M P O'Connell; S M Krzysik-Walker; R Moaddel; M Bernier
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells.

Authors:  Karin Eichele; Ulrike Weinzierl; Robert Ramer; Kay Brune; Burkhard Hinz
Journal:  Pharm Res       Date:  2006-11-08       Impact factor: 4.200

Review 5.  Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth.

Authors:  Rukiyah Van Dross; Eman Soliman; Shalini Jha; Travious Johnson; Somnath Mukhopadhyay
Journal:  Life Sci       Date:  2012-10-12       Impact factor: 5.037

Review 6.  Changes in the endocannabinoid system may give insight into new and effective treatments for cancer.

Authors:  Gianfranco Alpini; Sharon Demorrow
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

7.  R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway.

Authors:  Karin Eichele; Robert Ramer; Burkhard Hinz
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

8.  Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.

Authors:  Antje Scholl; Igor Ivanov; Burkhard Hinz
Journal:  Oncotarget       Date:  2016-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.